Notwithstanding promising clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable opposition from managed care entities. The companies are typically building barriers to reimbursement, such as steep cost criteria and prior authorization that hinder user opportunity. Mar… Read More